Expanded newborn screening: Implications for genomic medicine

Annual Review of Medicine

Volumn 59, Issue , 2008, Pages 163-175

  McCabe, Linda L ^a,b   McCabe, Edward R B ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California   (United States)

^c CALIFORNIA NANOSYSTEMS INSTITUTE   (United States)

Author keywords

Continuous quality improvement (CQI); Tandem mass spectrometry (MS MS); Two tiered screening

Indexed keywords

EVIDENCE BASED MEDICINE; GENETIC ANALYSIS; GENOMICS; HUMAN; LABORATORY TEST; MEDICAL GENETICS; NEWBORN SCREENING; PRIORITY JOURNAL; REVIEW; TANDEM MASS SPECTROMETRY;

GENETICS, MEDICAL; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; TANDEM MASS SPECTROMETRY;

EID: 39649108670     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.59.110106.132016     Document Type: Review

References (56)

1. Watson MS, Mann MY, Lloyd-Puryear MA, et al. 2006. Newborn screening: toward a uniform screening panel and system - executive summary. Genet. Med. 8:1S-11S
2. McCabe LL, McCabe ERB. 2008. DNA: Promise and Peril. Berkeley: Univ. Calif. Press. In press
3. McCabe E. 2001. Clinical genetics: compassion, access, science and advocacy. Genet. Med. 3:426-29
4. Khoury MJ, McCabe LL, McCabe ERB. 2003. Population screening in the age of genomic medicine. N. Engl. J. Med. 348:50-58
5. Guthrie R. 1962. Screening for "inborn errors of metabolism" in the newborn infant - a multiple test program. Birth Defects Orig. Artic. Ser. IV:92-98
6. Guthrie R, Susi A. 1963. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 32:338-43
7. Therrell BL, Panny SR, Davidson A, et al. 1992. US newborn screening system guidelines: statement of the Council of Regional Networks for Genetic Services (CORN). Screening 1:135-47
8. Pass KA, Lane PA, Fernhoff PM, et al. 2000. US newborn screening system guidelines II: follow-up of children, diagnosis, management and evaluation - statement of the Council of Regional Networks for Genetic Services (CORN). J. Pediatr. 137:S1-S46
9. American Academy of Pediatrics (AAP) Newborn Screening Task Force. 2000. Serving the family from birth to the medical home. Newborn screening: a blueprint for the future - a call for a national agenda on state newborn screening programs. Pediatrics 106:386-427
10. Therrell B. 2001. US newborn screening policy dilemmas for the twenty-first century. Mol. Genet. Metab. 74:64-74
11. McCabe LL, Therrell BL, McCabe ERB. 2002. Newborn screening: rationale for a comprehensive, fully integrated public health system. Mol. Genet. Metab. 77:267-73
12. Gaston MH, Verter JI, Woods G, et al. 1986. Prophylaxis with oral penicillin in children with sickle cell anemia - a randomized trial. N. Engl. J. Med. 314:1593-99
13. Consensus Panel, National Institutes of Health. 1987. Newborn screening for sickle cell disease and other hemoglobinopathies. JAMA 258:1205-9
14. Wilson JMG, Jungner G. 1968. Principles and practice of screening for disease. Public Health Pap. No. 34. Geneva: World Health Org.
15. Committee for the Study of Inborn Errors of Metabolism. 1975. In Genetic Screening Programs, Principles, and Research, pp. 9, 200-13. Washington, DC: Natl. Acad. Sci.
16. McCabe LL, McCabe ERB. 2002. Newborn screening as a model for population screening. Mol. Genet. Metab. 75:299-307
17. Kotzer AM, McCabe ERB. 1988. Newborn screening for inherited metabolic disease: principles and practice. Neonatal Netw. 6:15-19
18. American Society of Human Genetics. 1996. Statement on informed consent for genetic research. Am. J. Hum. Genet. 59:471-74
19. Public Perspectives on Genetic Discrimination. 2004. http://www4.od. nih.gov/oba/sacghs/reports/Public_Perspectives_GenDiscrim.pdf (Sep.-Nov.)
20. Alexander D, van Dyck PC. 2006. A vision of the future of newborn screening. Pediatrics 117:S350-54
21. Zhang Y-H, McCabe LL, Wilborn M, et al. 1994. Application of molecular genetics in public health: improved follow-up in a neonatal hemoglobinopathy screening program. Biochem. Med. Metab. Biol. 52:27-35
22. Schulze A, Lidner M, Kohlmuller D, et al. 2003. Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. Pediatrics 111:1399-406
23. Frazier DM, Millington DS, McCandless SE, et al. 2006. The tandem mass spectrometry newborn screening experience in North Carolina. J. Inherit. Metab. Dis. 29:76-85
24. Feuchtbaum L, Lorey F, Faulkner L, et al. 2006. California's experience implementing a pilot newborn supplemental screening program using tandem mass spectrometry. Pediatrics 117:S261-69
25. Grosse SD, Khoury MJ, Greene CL, et al. 2006. The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: an update. Genet. Med. 8:205-12
26. Insinga RP, Laessig RH, Hoffman GL. 2002. Newborn screening with tandem mass spectrometry: examining its cost-effectiveness in the Wisconsin newborn screening panel. J. Pediatr. 141:524-31
27. Wilcken B, Haas M, Joy P, et al. 2007. Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study. Lancet 369:37-42
28. Dionisi-Vici C, Deodato F, Roschinger W, et al. 2005. "Classical" organic acidurias, propionic aciduria, methylmalonic aciduria and isovaleric aciduria: long-term outcome and effects of expanded newborn screening using tandem mass spectrometry. J. Inherit. Metab. Dis. 29:383-89
29. Schimmenti LA, Crombez EA, Schwahn BC, et al. 2007. Expanded newborn screening identifies maternal primary carnitine deficiency. Mol. Genet. Metab. 90:441-45
30. Feuchtbaum L, Cunningham G. 2006. Economic evaluation of tandem mass spectrometry screening in California. Pediatrics 117:S280-86
31. Autti-Ramo I, Makela M, Sintonen H, et al. 2005. Expanding screening for rare metabolic disease in the newborn: an analysis of costs, effect and ethical consequences for decision-making in Finland. Acta Pediatr. 94:1126-36
32. Carroll AE, Downs SM. 2006. Comprehensive cost utility analysis of newborn screening strategies. Pediatrics 117:S287-95
33. Feuchtbaum L, Faulkner L, Verghese S. 2006. Tandem mass spectrometry program implementation challenges for state newborn screening programs: national survey of barriers and issues. Pediatrics 117:S253-60
34. Meikle PJ, Ranieri E, Simonsen H, et al. 2004. Newborn screening for lysosomal storage disorders: clinical evaluation of a two-tier strategy. Pediatrics 114:909-16
35. Gelb M, Turecek F, Scott CR, et al. 2006. Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. J. Inherit. Metab. Dis. 29:397-404
36. McGhee SA, McCabe ER. 2006. Genome-wide testing: genomic medicine. Pediatr. Res. 60:243-44
37. Stanczak CM, Chen Z, Zhang Y-H, et al. 2007. Deletion mapping in Xp21 for patients with complex glycerol kinase deficiency using SNP mapping arrays. Hum. Mutat. 28:235-42
38. McGhee SA, Stiehm ER, Cowan M, et al. 2005. Two-tiered universal newborn screening strategy for severe combined immunodeficiency. Mol. Genet. Metab. 86:427-30
39. McGhee SA, Stiehm ER, McCabe ER. 2005. Potential costs and benefits of newborn screening for severe combined immunodeficiency. J. Pediatr. 147:603-8
40. McCabe ER, Huang Y, Descartes M, et al. 1990. DNA from Guthrie spots for diagnosis of DMD by multiplex PCR. Biochem. Med. Metab. Biol. 44:294-95
41. Seltzer WK, Accurso F, Fall MZ, et al. 1991. Screening for cystic fibrosis: feasibility of molecular genetic analysis of dried blood specimens. Biochem. Med. Metab. Biol. 46:105-9
42. Bhardwaj U, Zhang Y-H, Blackburn W, et al. 2002. Rapid confirmation of Southeast Asian and Filipino alpha-thalassemia genotypes from newborn screening specimens. Am. J. Hematol. 71:56-58
43. Bhardwaj U, Zhang Y-H, McCabe ER. 2003. Neonatal hemoglobinopathy screening: molecular genetic technologies. Mol. Genet. Metab. 80:129-37
44. Bhardwaj U, Zhang Y-H, Lorey F, et al. 2005. Molecular genetic confirmatory testing from newborn screening samples from the common African-American, Asian Indian, Southeast Asian, and Chinese beta-thalassemia mutations. Am. J. Hematol. 78:249-55
45. Bhardwaj U, McCabe ER. 2005. Multiplex-PCR assay for the deletions causing hereditary persistence of fetal hemoglobin. Mol. Diagn. 9:151-56
46. Dipple KM, McCabe ER. 2000. Phenotypes of patients with "simple" Mendelian disorders are complex traits: thresholds, modifiers, and systems dynamics. Am. J. Hum. Genet. 66:1729-35
47. Dipple KM, McCabe ER. 2000. Modifier genes convert "simple" Mendelian disorders to complex traits. Mol. Genet. Metab. 71:43-50
48. Vockley J, Rinaldo P, Bennett MJ, et al. 2000. Synergistic heterozygosity: disease resulting from multiple partial defects in one or more metabolic pathways. Mol. Genet. Metab. 71:10-18
49. Dipple KM, Zhang Y-H, Huang B-L, et al. 2001. Glycerol kinase deficiency: evidence from complexity in a single gene disorder. Hum. Genet. 109:55-62
50. Dipple KM, Phelan JK, McCabe ER. 2001. Consequences of complexity within biological networks: robustness and health, or vulnerability and diseases. Mol. Genet. Metab. 74:45-50
51. Sriram G, Martinez JA, McCabe ER, et al. 2005. Single-gene disorders: What role could moonlighting enzymes play? Am. J. Hum. Genet. 76:911-24
52. Sidransky E. 2006. Heterozygosity for a Mendelian disorder as a risk factor for complex disease. Clin. Genet. 70:275-82
53. Rinaldo P, Tortorelli S, Matern D. 2004. Recent developments and new applications of tandem mass spectrometry in newborn screening. Curr. Opin. Pediatr. 16:427-33
54. Rhead WJ. 2006. Newborn screening for medium-chain-acyl-CoA dehydrogenase deficiency: a global perspective. J. Inherit. Metab. Dis. 29:370-77
55. Rinaldo P, Zafari S, Tortorelli S, et al. 2006. Making the case for objective performance metrics in newborn screening by tandem mass spectrometry. Merit. Retard. Dev. Disabil. Res. Rev. 12:255-61
56. Fletcher JM. 2006. Screening for lysosomal storage disorders - a clinical perspective. J. Inherit. Metab. Dis. 29:405-8